Circulating Tumor Cells Market Size, Share and Growth 2034
Circulating Tumor Cells Market Growth, Size, Trends Analysis - By Technology, By Application, By Product, By End-User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Sep-2025 | Report ID: PHAR2530 | Pages: 1 - 253 | Formats*: |
| Category : Pharmaceutical | |||
Circulating Tumor Cells Market Introduction and Overview
According to SPER Market Research, the Global Circulating Tumor Cells Market is estimated to reach USD 41.68 billion by 2034 with a CAGR of 12.47%.
The report includes an in-depth analysis of the Global Circulating Tumor Cells Market, including market size and trends, product mix, Applications, and supplier analysis. The global market for circulating tumor cells was valued at approximately USD 12.87 billion in 2024 and is projected to expand at a compound annual growth rate (CAGR) of 12.47% from 2025 to 2034. The growth of the circulating tumor cells market is driven by several factors, including the increasing incidence of cancer, technological advancements, and heightened awareness regarding cancer. Furthermore, innovations in chip technology represent another significant factor propelling market expansion.
By Technology Insights:
The circulating tumor cells market is categorized by technology into CTC detection and enrichment methods, CTC direct detection methods, and CTC analysis. The segment for CTC detection and enrichment methods is further divided into immunocapture, size-based separation, density-based separation, and combined methods. In 2024, the CTC detection and enrichment method segment accounted for the largest revenue share. The capability to detect and enrich CTCs from a patient's blood sample offers significant insights into tumor heterogeneity, metastatic potential, and treatment resistance. These methodologies allow researchers and clinicians to analyze CTCs at the cellular level, revealing essential information about tumor biology and facilitating the development of targeted therapies.
By Application Insights:
In terms of application, the CTC market is divided into research and clinical applications. The research segment is further categorized into cancer stem cell & tumorogenesis research and drug/therapy development. In 2024, the research segment generated the highest revenue. Circulating tumor cells (CTCs) are extensively utilized in cancer research, providing valuable insights into tumor biology and cancer prognosis. Additionally, CTCs can be employed for disease monitoring and early detection of metastasis, enabling timely intervention and enhancing patient outcomes. Furthermore, the increasing interest of researchers in CTCs and their various applications in cancer research is anticipated to boost the trends within this segment.
By Product Insights:
The circulating tumor cells market is divided by product into devices or systems, kits & assays, and consumables. In 2024, the devices or systems segment captured the largest market share and is expected to experience significant growth throughout the analysis period. The notable increase in the adoption of devices or systems for isolating circulating tumor cells (CTCs) is linked to the rising use of CTCs in cancer diagnosis, prognosis, and treatment monitoring. These devices and systems provide enhanced sensitivity, specificity, and efficiency in extracting CTCs from peripheral blood samples. Their user-friendliness, scalability, and compatibility have further accelerated their widespread adoption.
By End-User Insights:
In terms of end-user, the circulating tumor cells market is classified into research and academic institutes, hospitals and clinics, and diagnostic centers. The research and academic institute segment accounted for a substantial market share in 2024. The increasing use of CTCs in research and academic settings for cancer-related studies is driving the growth of this segment. Likewise, the rising incidence of cancer worldwide is boosting the demand for research, thereby contributing to the revenue of this segment.
Regional Insights:
In 2024, North America led the circulating tumor cells market and is expected to experience substantial growth throughout the forecast period. The rising cancer prevalence in the region, along with advancements in diagnostic technologies and growing awareness among healthcare professionals, has fostered the thriving CTCs market. Additionally, a strong healthcare infrastructure, combined with considerable investments in research and development, has facilitated the emergence of innovative techniques for CTC detection and analysis. Moreover, the region's strong focus on precision medicine and targeted therapies has further intensified the demand for CTC-based diagnostic and monitoring tools.
Market Competitive Landscape:
Prominent players in the circulating tumor cells market include QIAGEN, Bio-Techne Corporation, Precision Medicine Group, LLC, Bio-Rad Laboratories, Inc, Natera, Inc, and Illumina, Inc. These companies are actively engaged in the development, production, and commercialization of technologies and devices for CTC detection, offering a range of solutions from cell enrichment kits to automated systems and molecular analysis platforms. They continue to drive market growth through their innovative contributions to liquid biopsy technologies, non-invasive cancer diagnostics, and personalized oncology solutions.
Recent Developments:
January 2025: ANGLE announced the successful completion of a multi-center study that validated the broader capture of CTC phenotypes using the Parsortix PC1 system in cases of metastatic breast cancer.
In March 2024, Bio-Rad Laboratories, Inc. introduced validated antibodies for the enumeration of rare cells and circulating tumor cells (CTCs), thereby augmenting the resources available for CTC research and diagnostics.
March 2024: Bio-Rad Laboratories unveiled validated antibodies for rare cell enumeration on its Genesis Cell Isolation System, thereby enhancing the accuracy of CTC staining for studies on tumor heterogeneity.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Technology, By Application, By Product, By End-User |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | QIAGEN, Bio-Techne Corporation, Precision Medicine Group, LLC, Bio-Rad Laboratories, Inc, Natera, Inc, Illumina, Inc, Cell Microsystems, Greiner Bio One International GmbH, Ikonisys Inc, Miltenyi Biotec, Creative Bioarray, BioFluidica. |
- Global Circulating Tumor Cells Market Size (FY 2021-FY 2034)
- Overview of Global Circulating Tumor Cells Market
- Segmentation of Global Circulating Tumor Cells Market By Technology (CTC Detection and Enrichment Method, CTC Direct Detection Methods, CTC Analysis)
- Segmentation of Global Circulating Tumor Cells Market By Application (Research, Clinical)
- Segmentation of Global Circulating Tumor Cells Market By Product (Devices or Systems, Kits & assays, Consumables)
- Segmentation of Global Circulating Tumor Cells Market By End-User (Research and Academic Institutes, Hospital and Clinics, Diagnostic Centers)
- Statistical Snap of Global Circulating Tumor Cells Market
- Expansion Analysis of Global Circulating Tumor Cells Market
- Problems and Obstacles in Global Circulating Tumor Cells Market
- Competitive Landscape in the Global Circulating Tumor Cells Market
- Details on Current Investment in Global Circulating Tumor Cells Market
- Competitive Analysis of Global Circulating Tumor Cells Market
- Prominent Players in the Global Circulating Tumor Cells Market
- SWOT Analysis of Global Circulating Tumor Cells Market
- Global Circulating Tumor Cells Market Future Outlook and Projections (FY 2025-FY 2034)
- Recommendations from Analyst
1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
2. Research Methodology
- 2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
- 2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
- 2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
5. Market variable and outlook
- 5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
- 5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
- 5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
- 5.4. Heat Map Analysis
6. Competitive Landscape
- 6.1. Global Circulating Tumor Cells Market Manufacturing Base Distribution, Sales Area, Product Type
- 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Circulating Tumor Cells Market
7. Global Circulating Tumor Cells Market, By Technology (USD Million) 2021-2034
- 7.1. CTC Detection and Enrichment Method
- 7.1.1. Immunocapture
- 7.1.2. Size-based Separation
- 7.1.3. Density-based Separation
- 7.1.4. Combined Methods
- 7.2. CTC Direct Detection Methods
- 7.2.1. SERS (Surface-enhanced Raman Spectroscopy)
- 7.2.2. Microscopy
- 7.2.3. Other Direct Detection Methods
- 7.3. CTC Analysis
8. Global Circulating Tumor Cells Market, By Application (USD Million) 2021-2034
- 8.1. Research
- 8.1.1. Cancer Stem Cell & Tumorogenesis Research
- 8.1.2. Drug/Therapy Development
- 8.2. Clinical
- 8.2.1. Screening and Monitoring
- 8.2.2. Risk Assessment
9. Global Circulating Tumor Cells Market, By Product (USD Million) 2021-2034
- 9.1. Devices or Systems
- 9.2. Kits & assays
- 9.3. Consumables
10. Global Circulating Tumor Cells Market, By End-User (USD Million) 2021-2034
- 10.1. Research and Academic Institutes
- 10.2. Hospital and Clinics
- 10.3. Diagnostic Centers
11. Global Circulating Tumor Cells Market, (USD Million) 2021-2034
- 11.1. Global Circulating Tumor Cells Market Size and Market Share
12. Global Circulating Tumor Cells Market, By Region, (USD Million) 2021-2034
- 12.1. Asia-Pacific
- 12.1.1. Australia
- 12.1.2. China
- 12.1.3. India
- 12.1.4. Japan
- 12.1.5. South Korea
- 12.1.6. Rest of Asia-Pacific
- 12.2. Europe
- 12.2.1. France
- 12.2.2. Germany
- 12.2.3. Italy
- 12.2.4. Spain
- 12.2.5. United Kingdom
- 12.2.6. Rest of Europe
- 12.3. Middle East and Africa
- 12.3.1. Kingdom of Saudi Arabia
- 12.3.2. United Arab Emirates
- 12.3.3. Qatar
- 12.3.4. South Africa
- 12.3.5. Egypt
- 12.3.6. Morocco
- 12.3.7. Nigeria
- 12.3.8. Rest of Middle-East and Africa
- 12.4. North America
- 12.4.1. Canada
- 12.4.2. Mexico
- 12.4.3. United States
- 12.5. Latin America
- 12.5.1. Argentina
- 12.5.2. Brazil
- 12.5.3. Rest of Latin America
13. Company Profile
- 13.1. QIAGEN
- 13.1.1. Company details
- 13.1.2. Financial outlook
- 13.1.3. Product summary
- 13.1.4. Recent developments
- 13.2. Bio-Techne Corporation
- 13.2.1. Company details
- 13.2.2. Financial outlook
- 13.2.3. Product summary
- 13.2.4. Recent developments
- 13.3. Precision Medicine Group, LLC
- 13.3.1. Company details
- 13.3.2. Financial outlook
- 13.3.3. Product summary
- 13.3.4. Recent developments
- 13.4. Bio-Rad Laboratories, Inc
- 13.4.1. Company details
- 13.4.2. Financial outlook
- 13.4.3. Product summary
- 13.4.4. Recent developments
- 13.5. Natera, Inc
- 13.5.1. Company details
- 13.5.2. Financial outlook
- 13.5.3. Product summary
- 13.5.4. Recent developments
- 13.6. Illumina, Inc
- 13.6.1. Company details
- 13.6.2. Financial outlook
- 13.6.3. Product summary
- 13.6.4. Recent developments
- 13.7. Cell Microsystems
- 13.7.1. Company details
- 13.7.2. Financial outlook
- 13.7.3. Product summary
- 13.7.4. Recent developments
- 13.8. Greiner Bio One International GmbH
- 13.8.1. Company details
- 13.8.2. Financial outlook
- 13.8.3. Product summary
- 13.8.4. Recent developments
- 13.9. Ikonisys Inc
- 13.9.1. Company details
- 13.9.2. Financial outlook
- 13.9.3. Product summary
- 13.9.4. Recent developments
- 13.10. Miltenyi Biotec
- 13.10.1. Company details
- 13.10.2. Financial outlook
- 13.10.3. Product summary
- 13.10.4. Recent developments
- 13.11. Creative Bioarray
- 13.11.1. Company details
- 13.11.2. Financial outlook
- 13.11.3. Product summary
- 13.11.4. Recent developments
- 13.12. BioFluidica
- 13.12.1. Company details
- 13.12.2. Financial outlook
- 13.12.3. Product summary
- 13.12.4. Recent developments
- 13.13. Others
14. Conclusion
15. List of Abbreviations
16. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Circulating Tumor Cells Market is projected to reach USD 41.68 billion by 2034, growing at a CAGR of of 12.47% during the forecast period.
Circulating Tumor Cells Market grew in Market size from 2025. The Market is expected to reach USD 41.68 billion by 2034, at a CAGR of 12.47% during the forecast period.
Circulating Tumor Cells Market CAGR of 12.47% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Circulating Tumor Cells Market size is USD 41.68 billion from 2025 to 2034.
Circulating Tumor Cells Market is covered By Technology, By Application, By Product, By End-User
The North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa is the highest Market share in the Circulating Tumor Cells Market.
QIAGEN, Bio-Techne Corporation, Precision Medicine Group, LLC, Bio-Rad Laboratories, Inc, Natera, Inc, Illumina, Inc, Cell Microsystems, Greiner Bio One International GmbH, Ikonisys Inc, Miltenyi Biotec, Creative Bioarray, BioFluidica.
The report includes an in-depth analysis of the Global Circulating Tumor Cells Market, including market size and trends, product mix, Applications, and supplier analysis.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
